## Barbara Hauser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8470510/publications.pdf

Version: 2024-02-01

1307366 996849 25 241 7 15 citations g-index h-index papers 27 27 27 297 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Communicating Absolute Fracture Risk Reduction and the Acceptance of Treatment for Osteoporosis. Calcified Tissue International, 2022, 110, 698-702.	1.5	6
2	Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup. Rheumatology Advances in Practice, 2022, 6, rkac017.	0.3	4
3	Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Rheumatology Advances in Practice, 2022, 6, rkac010.	0.3	O
4	The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides. Frontiers in Endocrinology, 2022, 13, 806361.	1.5	4
5	P136 $\hat{a}$ Methotrexate osteopathy - clinical and radiological characteristics in a case series of twenty-one patients. Rheumatology, 2022, 61, .	0.9	O
6	The Effect of Anti-rheumatic Drugs on the Skeleton. Calcified Tissue International, 2022, 111, 445-456.	1.5	4
7	P210â€fTocilizumab versus prednisolone only treatment for giant cell arteritis: an observational study. Rheumatology, 2021, 60, .	0.9	O
8	$P205\hat{a} \in f$ The contemporary presentation and management of giant cell arteritis with large vessel vasculitis. Rheumatology, 2021, 60, .	0.9	0
9	Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups. Journal of Clinical Medicine, 2021, 10, 1403.	1.0	12
10	P112â $\in$ f Teriparatide versus anti-resorptive treatment in rheumatoid arthritis patients with severe osteoporosis: an observational study. Rheumatology, 2021, 60, .	0.9	0
11	Takayasu Arteritis. Journal of Clinical Rheumatology, 2021, 27, S406-S408.	0.5	1
12	When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis. Frontiers in Endocrinology, 2021, 12, 782118.	1.5	14
13	42.â€ $f$ Large vessel vasculitis with rapidly expanding aortic aneurysm. Rheumatology Advances in Practice, 2019, 3, .	0.3	1
14	101â€fEfficacy of tocilizumab use in giant cell arteritis (GCA) and Takayasu arteritis (TA) patients allowing glucocorticoid dose reduction. Rheumatology, 2019, 58, .	0.9	0
15	$011\hat{a} \in f$ Takayasu arteritis: a case series of unusual complications and comorbidities. Rheumatology, 2018, 57, .	0.9	O
16	The Role of Autoantibodies in Bone Metabolism and Bone Loss. Calcified Tissue International, 2018, 102, 522-532.	1.5	11
17	A case of hypocomplementaemic urticarial vasculitis with cardiac valve involvement successfully treated with cyclophosphamide and highâ€dose glucocorticoids. International Journal of Rheumatic Diseases, 2017, 20, 1850-1852.	0.9	8
18	Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcified Tissue International, 2017, 101, 375-383.	1.5	25

#	Article	IF	Citations
19	200â€∫Autoantibodies to Osteoprotegerin and Bone Mineral Density in Axial Spondyloarthritis. Rheumatology, 2016, , .	0.9	0
20	Characterisation of Osteoprotegerin Autoantibodies in Coeliac Disease. Calcified Tissue International, 2015, 97, 125-133.	1.5	14
21	Systemic Manifestations of Hypocomplementemic Urticarial Vasculitis: Comment on the Article by Jachiet et al. Arthritis and Rheumatology, 2015, 67, 1984-1985.	2.9	2
22	Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1631-1632.	0.5	16
23	Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology, 2014, 53, 1759-1766.	0.9	119
24	Detection of autoantibodies to osteoprotegerin in patients with rheumatoid arthritis and their association with disease activity. Bone Abstracts, $0$ , , .	0.0	0
25	Osteoprotegerin autoantibodies are independently associated with low hip bone mineral density and increased fracture risk in patients with ankylosing spondylitis. Bone Abstracts, 0, , .	0.0	0